The included studies comprised 77,083 patients (56.96% males; n = 43,905) and assessed SGLT2 inhibitors compared with a placebo or any other glucose-lowering agent among the targeted population with HF and T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.